Stem cell transplantation in Multiple Sclerosis: Safety and Ethics

@article{Silani2008StemCT,
  title={Stem cell transplantation in Multiple Sclerosis: Safety and Ethics},
  author={Vincenzo Silani and Lidia Cova},
  journal={Journal of the Neurological Sciences},
  year={2008},
  volume={265},
  pages={116-121}
}
  • V. SilaniL. Cova
  • Published 15 February 2008
  • Medicine, Biology
  • Journal of the Neurological Sciences

Stem Cell Therapy - Approach for Multiple Sclerosis Treatment

Focusing on safety issues, while bridging from the basic SC sciences to the clinical transplantation trials, has a crucial role in cellular therapy programs.

Autologous Hematopoietic Stem Cell Transplantation as a Potential Treatment for Multiple Sclerosis Patients

Research suggests that there may be an alternative treatment plan which involves the use of an autologous Hematopoietic Stem Cell Transplant, which has shown to halt the progression of the disease as well as reduce clinical relapses.

Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis

This case report is a novel evidence for autologous hematopoietic stem cell transplantation (HSCT) in progressive MS, and needs to be tested in well-designed randomized trial.

Adult stem cell therapy for autoimmune disease.

  • E. Choi
  • Biology, Medicine
    International journal of stem cells
  • 2009
MSC would make a significant contribution to stem cell therapy or combination therapy for ameliorating symptoms and curing autoimmune disease by searching and studying the appropriate therapeutic gene and acquiring the synergy effect and the combined advantage of gene therapy and stem cell Therapy.

Autologous hematopoietic stem cell transplantation in autoimmune diseases

Growing experience with autologous HCST in autoimmune diseases has progressively reduced concerns about transplant-related mortality and secondary myelodysplasia/leukemia, and a sustained complete remission seems to be within the reach of autografting in some autoimmune diseases; in others, the indications, risks and benefits of autodeficiency need to be better defined.

Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination.

It is found that mesenchymal stem cells from human umbilical cord (hUC-MSCs) could restore behavioral functions and attenuate the histopathological deficits of experimental autoimmune encephalomyelitis mice over the long term by suppression of perivascular immune cell infiltrations and reduction in both demyelination and axonal injury in the spinal cord.

Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement?

Several mechanisms such as cell fusion, neurotrophic factor release, endogenous stem cell proliferation, and transdifferentiation may explain positive therapeutic results in preclinical animal models, in addition to replacement of lost motor neurons.

[Intravenous immunoglobulins in multiple sclerosis. An update].

Overall IVIG may be considered a safe second-line compound in patients with relapsing-remitting MS, however, efficacy, long-term consequences, and optimal dosage of IVIG have not been unequivocally ascertained as yet.

References

SHOWING 1-10 OF 38 REFERENCES

Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis

The treatment with intense immune ablation followed by ASCT of three patients with malignant MS whose clinical course indicated a dramatically poor prognosis succeeded in halting the rapidly worsening course of disease.

Stem-cell therapy for amyotrophic lateral sclerosis

Autologous Stem Cell Transplantation in Progressive Multiple Sclerosis—An Interim Analysis of Efficacy

These results appear better than those achieved by any other treatment of progressive multiple sclerosis, including beta-interferon, but they need to be confirmed by other open or controlled studies in view of the well-known difficulty of judging objectively the effect of a treatment in patients with this disease.

Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis.

The present results indicate that ongoing demyelination and axonal degeneration exist despite pronounced immunosuppression in multiple sclerosis patients with high expanded disability system scores despite autologous stem cell transplantation.

Stem therapy for ALS: hope and reality.

  • V. SilaniN. Leigh
  • Biology, Medicine
    Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
  • 2003
The recent breakthroughs in stem cell research might nevertheless provide possibilities for neural implantation and cell replacement therapy for patients with ALS, as well as the potential impact of these new approaches to neurodegenerative diseases.

Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis

The results of the Italian phase 2 GITMO study support a role for intense immunosuppression followed by ASCT as treatment in rapidly evolving MS cases unresponsive to conventional therapies.

Stem Cell Therapy for ALS: Hope and RealityA discussion paper from the Executive of the European ALS Consortium

The recent breakthroughs in stem cell research might nevertheless provide possibilities for neural implantation and cell replacement therapy for patients with ALS, as well as the potential impact of these new approaches to neurodegenerative diseases.

Autologous Peripheral Blood Stem Cell Transplantation for Severe Multiple Sclerosis

  • L. SuJuan Xu D. Lu
  • Medicine, Biology
    International journal of hematology
  • 2006
Autologous hematopoietic stem cell transplantation (auto-HSCT) proved to be safe and beneficial for some MS patients and further studies are needed to establish the merit of this procedure for MS patients.

Hematopoietic stem cell transplantation for multiple sclerosis

Autologous HSCT suggest positive early results in the management of progressive MS and is feasible and is being utilised in the planning of future trials to reduce transplant related mortality.